{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:28:03Z","timestamp":1762507683596,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AI078498"],"award-info":[{"award-number":["P30 AI078498"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40801-019-0147-3","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T17:33:08Z","timestamp":1550079188000},"page":"37-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tolerability of Isoniazid Preventive Therapy in an HIV-Infected Cohort of Paediatric and Adolescent Patients on Antiretroviral Therapy from a Resource-Limited Setting: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-7108","authenticated-orcid":false,"given":"Tinashe","family":"Mudzviti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8931-4484","authenticated-orcid":false,"given":"Tinei","family":"Shamu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3756-3523","authenticated-orcid":false,"given":"Cleophas","family":"Chimbetete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilda","family":"Munengerwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Bote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Pascoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"key":"147_CR1","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Global tuberculosis report. Geneva: WHO Library cataloguing-in-publication data; 2014."},{"issue":"19","key":"147_CR2","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1001\/jama.1986.03380190079029","volume":"256","author":"DN Rose","year":"1986","unstructured":"Rose DN, Schechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis A decision analysis for low-risk tuberculin reactors. JAMA. 1986;256(19):2709\u201313.","journal-title":"JAMA."},{"issue":"Suppl 5","key":"147_CR3","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/01.aids.0000391022.95412.a6","volume":"24","author":"B Durovni","year":"2010","unstructured":"Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, et al. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB\/HIV in Rio (THRio) study. AIDS. 2010;24(Suppl 5):S49\u201356. \n                    https:\/\/doi.org\/10.1097\/01.aids.0000391022.95412.a6\n                    \n                  .","journal-title":"AIDS."},{"issue":"2","key":"147_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5501\/wjv.v4.i2.105","volume":"4","author":"C Akolo","year":"2015","unstructured":"Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, et al. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol. 2015;4(2):105\u201312. \n                    https:\/\/doi.org\/10.5501\/wjv.v4.i2.105\n                    \n                  .","journal-title":"World J Virol."},{"issue":"Suppl 5","key":"147_CR5","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1097\/01.aids.0000391019.10661.66","volume":"24","author":"AD Grant","year":"2010","unstructured":"Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ. Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS. 2010;24(Suppl 5):S29\u201336. \n                    https:\/\/doi.org\/10.1097\/01.aids.0000391019.10661.66\n                    \n                  .","journal-title":"AIDS."},{"issue":"1","key":"147_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1011214","volume":"365","author":"SA Madhi","year":"2011","unstructured":"Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011;365(1):21\u201331. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1011214\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"1","key":"147_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5588\/ijtld.11.0820","volume":"17","author":"SM Le Roux","year":"2013","unstructured":"Le Roux SM, Cotton MF, Myer L, le Roux DM, Schaaf HS, Lombard CJ, et al. Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules. Int J Tuberc Lung Dis. 2013;17(1):26\u201331. \n                    https:\/\/doi.org\/10.5588\/ijtld.11.0820\n                    \n                  .","journal-title":"Int J Tuberc Lung Dis."},{"issue":"1","key":"147_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5588\/pha.16.0102","volume":"7","author":"KC Takarinda","year":"2017","unstructured":"Takarinda KC, Choto RC, Harries AD, Mutasa-Apollo T, Chakanyuka-Musabhu C. Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe. Public Health Action. 2017;7(1):55\u201360.","journal-title":"Public Health Action."},{"key":"147_CR9","doi-asserted-by":"publisher","first-page":"CD006418","DOI":"10.1002\/14651858.cd006418.pub3","volume":"8","author":"M Zunza","year":"2017","unstructured":"Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst Rev. 2017;8:CD006418. \n                    https:\/\/doi.org\/10.1002\/14651858.cd006418.pub3\n                    \n                  .","journal-title":"Cochrane Database Syst Rev."},{"issue":"7585","key":"147_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/bmj.39000.486400.55","volume":"334","author":"HJ Zar","year":"2007","unstructured":"Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007;334(7585):136. \n                    https:\/\/doi.org\/10.1136\/bmj.39000.486400.55\n                    \n                  .","journal-title":"BMJ"},{"key":"147_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ajme.2017.03.002","volume":"54","author":"PA Mataranyika","year":"2018","unstructured":"Mataranyika PA, Kibuule D, Kalemeera F, Kaura H, Godman B, Rennie TW. Liver enzyme elevations in a cohort of HIV\/AIDS patients on first-lineantiretroviral therapy in Namibia: findings and implications. Alexandria J Med. 2018;54:49\u201356.","journal-title":"Alexandria J Med."},{"issue":"9777","key":"147_CR12","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","volume":"377","author":"T Samandari","year":"2011","unstructured":"Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9777):1588\u201398. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(11)60204-3\n                    \n                  .","journal-title":"Lancet"},{"issue":"2","key":"147_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1164\/rccm.200911-1783OC","volume":"182","author":"Z Tedla","year":"2010","unstructured":"Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, Motsamai O, et al. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. Am J Respir Crit Care Med. 2010;182(2):278\u201385. \n                    https:\/\/doi.org\/10.1164\/rccm.200911-1783OC\n                    \n                  .","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"147_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.5588\/ijtld.12.0427","volume":"17","author":"EH Decloedt","year":"2013","unstructured":"Decloedt EH, Mwansa-Kambafwile J, van der Walt JS, McIlleron H, Denti P, Smith P, et al. The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals. Int J Tuberc Lung Dis. 2013;17(3):333\u20135. \n                    https:\/\/doi.org\/10.5588\/ijtld.12.0427\n                    \n                  .","journal-title":"Int J Tuberc Lung Dis."},{"issue":"10","key":"147_CR15","doi-asserted-by":"publisher","first-page":"e0186726","DOI":"10.1371\/journal.pone.0186726","volume":"12","author":"T Shamu","year":"2017","unstructured":"Shamu T, Chimbetete C, Shawarira-Bote S, Mudzviti T, Luthy R. Outcomes of an HIV cohort after a decade of comprehensive care at Newlands Clinic in Harare, Zimbabwe: TENART cohort. PLoS One. 2017;12(10):e0186726. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0186726\n                    \n                  .","journal-title":"PLoS One"},{"issue":"1","key":"147_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12916-018-1033-7","volume":"16","author":"CD Tweed","year":"2018","unstructured":"Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, et al. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med. 2018;16(1):46. \n                    https:\/\/doi.org\/10.1186\/s12916-018-1033-7\n                    \n                  .","journal-title":"BMC Med."},{"unstructured":"Ministry of Health and Child Care Zimbabwe. Guidelines for antiretroviral therapy for the prevention and treatment of HIV in Zimbabwe, 2013. In: Directorate TAaT, editor. 2013.","key":"147_CR17"},{"issue":"9944","key":"147_CR18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","volume":"384","author":"MX Rangaka","year":"2014","unstructured":"Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384(9944):682\u201390. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)60162-8\n                    \n                  .","journal-title":"Lancet"},{"issue":"3","key":"147_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5588\/pha.13.0013","volume":"3","author":"EO Masini","year":"2013","unstructured":"Masini EO, Sitienei J, Weyeinga H. Outcomes of isoniazid prophylaxis among HIV-infected children attending routine HIV care in Kenya. Public Health Action. 2013;3(3):204\u20138. \n                    https:\/\/doi.org\/10.5588\/pha.13.0013\n                    \n                  .","journal-title":"Public Health Action."},{"doi-asserted-by":"crossref","unstructured":"Mudzviti T, Mandizvidza T, Ngara B, Chimbetete C, Maponga CC, Morse GD. Pill dumping in adolescents receiving a boosted protease inhibitor regimen as part of second-line antiretroviral therapy: experiences from an urban HIV clinic. World STI & HIV Congress; Brisbane Australia: Sexually Transmitted Infections; 2015. p. A33.3-A4.","key":"147_CR20","DOI":"10.1136\/sextrans-2015-052270.100"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-019-0147-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-019-0147-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-019-0147-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T23:56:47Z","timestamp":1589673407000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-019-0147-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["147"],"URL":"https:\/\/doi.org\/10.1007\/s40801-019-0147-3","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2019,2,13]]},"assertion":[{"value":"13 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors received no specific funding for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tinashe Mudzviti, Tinei Shamu, Cleophas Chimbetete, Tilda Munengerwa, Sandra Bote and Margaret Pascoe declare that no competing interests exist for the work undertaken.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}